Sickle Cell Disease Trial, Recruiting (NCT06497153)

Sickle Cell Disease Trial, Recruiting NCT06497153 Sponsor: Assistance Publique - Hôpitaux de Paris Condition: Sickle Cell Disease

Printed from Voxsanity (voxsanity.com.au) — NCT06497153 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Sickle Cell Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

The patient has sickle cell disease and is between 1 month and 17 years old
The patient is currently admitted to the Pediatric Intensive Care Unit (PICU) at Robert-Debré Hospital
Doctors suspect the patient may have a condition called acute chest syndrome (a serious lung complication of sickle cell disease)
The patient's legal guardian or the doctor responsible for the child has not objected to participation

Who may not be able to join:

The patient's parents or guardians have said they do not want the patient to take part
More than 6 hours have passed between the first lung ultrasound scan and the start of breathing support
The patient does not have social insurance (health coverage) (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 26 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Aurélie HAYOTTE, MD, Assistance Publique - Hôpitaux de Paris

Phone: +33.1.40.03.36.49

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06497153

Sponsor: Assistance Publique - Hôpitaux de Paris

Phase: Not Applicable

Status: Recruiting

Condition: Sickle Cell Disease

Trial contact: +33.1.40.03.36.49

More information: https://clinicaltrials.gov/study/NCT06497153

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

The patient has sickle cell disease and is between 1 month and 17 years old
The patient is currently admitted to the Pediatric Intensive Care Unit (PICU) at Robert-Debré Hospital
Doctors suspect the patient may have a condition called acute chest syndrome (a serious lung complication of sickle cell disease)
The patient's legal guardian or the doctor responsible for the child has not objected to participation

Who may not be able to join:

The patient's parents or guardians have said they do not want the patient to take part
More than 6 hours have passed between the first lung ultrasound scan and the start of breathing support
The patient does not have social insurance (health coverage) (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 26 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Assistance Publique - Hôpitaux de Paris

Registry

ClinicalTrials.gov

Start date

30 June 2024

Est. completion

30 June 2026

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Correlation coefficients between LUS scores (lung ultrasound) at H0, H8, H24, H48, H72 and duration of ventilation (invasive and non-invasive combined)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov